ad

3 Enterprise Software Services Company, Pharmaceuticals Company and Forgings Maker Stocks With a Strong Future Roadmap: Mastek, Eris Lifesciences and Happy Forgings

Mastek, Eris Lifesciences and Happy Forgings: ROE of 13.5% to 15.9% and FY22 to FY26 revenue CAGR of 14.2% to 22.9%. Prices as of 13 Nov 2026.


16 Nov 2026 • 2:21 pm

3 Enterprise Software Services Company, Pharmaceuticals Company and Forgings Maker Stocks With a Strong Future Roadmap: Mastek, Eris Lifesciences and Happy Forgings

Quick Answer

The three software, pharma and forging stocks to watch are Mastek, Eris Lifesciences and Happy Forgings. Their return on equity ranges from 13.5% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 14.2% to 22.9%. Eris Lifesciences leads on both return on equity at 15.9% and revenue growth at 22.9% a year. Prices are based on the 13 November 2026 close, and this article is educational, not investment advice.

Software, pharma and forging stocks offer a focused view of a sector where demand keeps widening. Mastek, Eris Lifesciences and Happy Forgings cover an enterprise software services company, a pharmaceuticals company and a forgings maker.

This list covers three software, pharma and forging stocks with complete current figures: Mastek, Eris Lifesciences and Happy Forgings. Every figure comes from the latest reported financials and the 13 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Software, Pharma and Forging Stocks?

Software, pharma and forging stocks are listed companies that provide enterprise software and digital services to global clients, make and sell medicines for chronic care, and make forged and machined parts for vehicles, aerospace and energy. Their earnings depend on client technology budgets, medicine demand and engineering demand.

Software, Pharma and Forging Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Mastek 1,514.9 5,673 13.6 17.9 13.5 0.15
Eris Lifesciences 1,307.2 15,618 23.5 36.0 15.9 0.60
Happy Forgings 1,955.8 17,630 53.9 50.7 14.2 0.15

On valuation, Mastek and Eris Lifesciences trade at a P/E below the industry P/E, while Happy Forgings trades above it, which reflects the growth the market already expects. Readers comparing software, pharma and forging stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Software, Pharma and Forging Stocks Have a Strong Roadmap in India?

Software, pharma and forging stocks have a strong roadmap in India because steady global spending on enterprise software, wider access to chronic care medicines and growing demand for engineered forgings keep widening the market for these companies.

  • Enterprise software. Global firms modernise their systems.
  • Pharmaceuticals. Chronic patients need regular medicines.
  • Forgings. Engines and machines need precise forged parts.

Why Mastek Features Among These Software, Pharma and Forging Stocks

Among the software, pharma and forging stocks on this list, Mastek is a digital engineering and cloud services company that serves clients in the United Kingdom, the United States and other regions, with a strong presence in public sector, retail and financial services.

In the June 2026 quarter, revenue grew 7.8% year on year to Rs 997 crore, while net profit rose 15.0% to Rs 106 crore. Revenue rose from Rs 2,220 crore in FY22 to Rs 3,769 crore in FY26, a compound annual growth rate of 14.2%.

Net profit grew from Rs 310 crore in FY23 to Rs 404 crore in FY26, which works out to a compound annual growth rate of 9.2%. The company has a return on equity of 13.5%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 5,673 crore. The stock trades at a P/E of 13.6, below the industry P/E of 17.9.

Roadmap: The company is expanding its cloud, data and software engineering work and deepening ties with existing clients. A focus on repeat engagements supports steady revenue.

What to watch: Follow client additions, order book momentum and growth in cloud and data services.

Why Eris Lifesciences Features Among These Software, Pharma and Forging Stocks

Among the enterprise software, medicine maker and engine part shares on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.

The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0.

Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore.

Roadmap: Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

What to watch: Check how smoothly acquired brands are integrated and how the injectables unit scales.

Why Happy Forgings Features Among These Software, Pharma and Forging Stocks

Among the three companies on this list, Happy Forgings is a Ludhiana-based maker of forged and machined components for engines, transmissions and axles, selling to commercial vehicle, off-highway, farm and industrial customers.

Revenue rose from Rs 866 crore in FY22 to Rs 1,577 crore in FY26, a compound annual growth rate of 16.2%. Net profit grew from Rs 142 crore in FY22 to Rs 302 crore in FY26, which works out to a compound annual growth rate of 20.7%.

In the June 2026 quarter, revenue grew 26.5% year on year to Rs 460 crore, while net profit rose 39.2% to Rs 91.5 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 17,630 crore. The stock trades at a P/E of 53.9, above the industry P/E of 50.7.

Roadmap: The company is adding machining capacity and widening its range to serve passenger vehicles, railways and aerospace, which reduces reliance on a single segment. Its focus on precision components supports long-term relationships with global customers.

What to watch: Monitor the pace of new capacity and the shift towards higher-value, fully machined parts.

Mastek vs Eris Lifesciences vs Happy Forgings on Key Financials

The table below sets the three software, pharma and forging stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Mastek 2,220 3,769 14.2% 404 10.7%
Eris Lifesciences 1,373 3,137 22.9% 648 20.6%
Happy Forgings 866 1,577 16.2% 302 19.1%

Eris Lifesciences posts the highest return on equity in this group at 15.9%. Mastek has the largest FY26 revenue at Rs 3,769 crore, and Eris Lifesciences shows the fastest revenue growth with a 22.9% compound annual rate. A useful habit with software, pharma and forging stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Company Q1 FY26 Revenue (Rs Cr) Q1 FY27 Revenue (Rs Cr) Year-on-Year Growth
Mastek 925 997 7.8%
Eris Lifesciences 776 876 12.9%
Happy Forgings 364 460 26.5%

Key Risks to Check Before Investing in Software, Pharma and Forging Stocks

Every theme carries risks that deserve a check before any decision. For these software, pharma and forging stocks, the main points are: Long-term enterprise software, medicine maker and engine part shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

  • Currency moves. Export earnings move with the rupee.
  • Regulatory approvals. Plant inspections and approvals can affect supplies.
  • Production cycles. Vehicle output can vary with demand.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter software, pharma and forging stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Software, Pharma and Forging Stocks

Software, pharma and forging stocks reward patient research into demand, execution and financial strength. Mastek, Eris Lifesciences and Happy Forgings each have a clear plan to grow. Based on the 13 November 2026 close, Mastek trades at Rs 1,514.9, Eris Lifesciences at Rs 1,307.2 and Happy Forgings at Rs 1,955.8. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these software, pharma and forging stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track software, pharma and forging stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are software, pharma and forging stocks?

Ans. Software, pharma and forging stocks are listed companies that provide enterprise software and digital services to global clients, make and sell medicines for chronic care, and make forged and machined parts for vehicles, aerospace and energy. Their earnings depend on client technology budgets, medicine demand and engineering demand. This list looks at three of them, Mastek, Eris Lifesciences and Happy Forgings, using reported FY22 to FY26 financials and the 13 November 2026 closing prices.

Which software, pharma and forging stocks are covered in this list?

Ans. This list covers Mastek, Eris Lifesciences and Happy Forgings. Based on the 13 November 2026 close, Mastek traded at Rs 1,514.9, Eris Lifesciences at Rs 1,307.2 and Happy Forgings at Rs 1,955.8. Their return on equity ranges from 13.5% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 14.2% to 22.9%.

Why do software, pharma and forging stocks have a strong future roadmap in India?

Ans. Software, pharma and forging stocks have a strong roadmap in India because steady global spending on enterprise software, wider access to chronic care medicines and growing demand for engineered forgings keep widening the market for these companies. The main drivers are as follows. Enterprise software. Global firms modernise their systems. Pharmaceuticals. Chronic patients need regular medicines. Forgings. Engines and machines need precise forged parts. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Mastek performed financially?

Ans. Revenue rose from Rs 2,220 crore in FY22 to Rs 3,769 crore in FY26, a compound annual growth rate of 14.2%. Net profit grew from Rs 310 crore in FY23 to Rs 404 crore in FY26, which works out to a compound annual growth rate of 9.2%. In the June 2026 quarter, revenue grew 7.8% year on year to Rs 997 crore, while net profit rose 15.0% to Rs 106 crore. The company has a return on equity of 13.5%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 5,673 crore. The stock trades at a P/E of 13.6, below the industry P/E of 17.9. Looking ahead, the company is expanding its cloud, data and software engineering work and deepening ties with existing clients. A focus on repeat engagements supports steady revenue.

How has Eris Lifesciences performed financially?

Ans. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

How has Happy Forgings performed financially?

Ans. Revenue rose from Rs 866 crore in FY22 to Rs 1,577 crore in FY26, a compound annual growth rate of 16.2%. Net profit grew from Rs 142 crore in FY22 to Rs 302 crore in FY26, which works out to a compound annual growth rate of 20.7%. In the June 2026 quarter, revenue grew 26.5% year on year to Rs 460 crore, while net profit rose 39.2% to Rs 91.5 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 17,630 crore. The stock trades at a P/E of 53.9, above the industry P/E of 50.7. Looking ahead, the company is adding machining capacity and widening its range to serve passenger vehicles, railways and aerospace, which reduces reliance on a single segment. Its focus on precision components supports long-term relationships with global customers.

What risks should investors check before buying software, pharma and forging stocks?

Ans. Investors should check a few risks before buying software, pharma and forging stocks. Currency moves. Export earnings move with the rupee. Regulatory approvals. Plant inspections and approvals can affect supplies. Production cycles. Vehicle output can vary with demand. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of software, pharma and forging stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 13 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down